S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Forecast, Price & News

$1.13
-0.08 (-6.61%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.07
$1.24
50-Day Range
$0.51
$1.43
52-Week Range
$0.24
$1.63
Volume
2.16 million shs
Average Volume
1.87 million shs
Market Capitalization
$210.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
77.0% Upside
$2.00 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.36mentions of Akebia Therapeutics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$378,208 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

362nd out of 1,012 stocks

Pharmaceutical Preparations Industry

160th out of 495 stocks


AKBA stock logo

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
Analyst Ratings for Akebia Therapeutics
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Why Shares of Akebia Therapeutics Were Up Tuesday
These 14 Biotech Stocks Hit New Highs, Did You Get In Early?
Akebia Therapeutics regains Nasdaq compliance
Akebia Therapeutics (AKBA) Gets a Hold from H.C. Wainwright
Q1 2023 Akebia Therapeutics Inc Earnings Call
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Company Calendar

Last Earnings
3/09/2023
Today
5/28/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKBA
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+77.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-92,560,000.00
Pretax Margin
-20.79%

Debt

Sales & Book Value

Annual Sales
$292.60 million
Book Value
($0.08) per share

Miscellaneous

Free Float
179,086,000
Market Cap
$210.10 million
Optionable
Optionable
Beta
0.74

Key Executives

  • John P. ButlerJohn P. Butler
    President, Chief Executive Officer & Director
  • Michel DahanMichel Dahan
    Chief Operating Officer & Senior Vice President
  • David A. SpellmanDavid A. Spellman
    Treasurer, Chief Financial & Accounting Officer
  • Steven K. BurkeSteven K. Burke
    Chief Medical Officer & SVP-Research & Development
  • Michael Rabinowitz
    Vice President-Research













AKBA Stock - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AKBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 12 month target prices for Akebia Therapeutics' shares. Their AKBA share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 77.0% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2023?

Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA shares have increased by 95.8% and is now trading at $1.13.
View the best growth stocks for 2023 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,070,000 shares, a decrease of 9.6% from the April 30th total of 4,500,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is currently 2.4 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings results on Thursday, March, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The biopharmaceutical company had revenue of $55.18 million for the quarter, compared to the consensus estimate of $48.35 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 235.17% and a negative net margin of 20.79%.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (8.72%), BlackRock Inc. (1.45%), Renaissance Technologies LLC (1.26%), State Street Corp (0.37%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Victory Capital Management Inc. (0.14%). Insiders that own company stock include David A Spellman, Dell Faulkingham, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $1.13.

How much money does Akebia Therapeutics make?

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $210.10 million and generates $292.60 million in revenue each year. The biopharmaceutical company earns $-92,560,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

The company employs 426 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -